Mesoblast is a Victoria-based regenerative medicine company that develops therapeutics for the treatment of inflammatory and cardiovascular diseases.Read more
Mesoblast's revenue is the ranked 8th among it's top 10 competitors. The top 10 competitors average 28M. Over the last four quarters, Mesoblast's revenue has grown by 52.9%. Specifically, in Q2 2021's revenue was $2M; in Q1 2021, it was $1.9M; in Q4 2020, it was $2.2M; in Q3 2020, Mesoblast's revenue was $1.3M.